Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro
Sabyasachi Biswas, Xiaobin Zhao, Andrew P. Mone, Xiaokui Mo, Melissa Vargo, David Jarjoura, John C. Byrd, Natarajan Muthusamy
20100601
2010 Jul 1
Leuk Res
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro
Leuk Res. 2010 Jul;34(7):925-931, Sabyasachi Biswas, Xiaobin Zhao, Andrew P. Mone, Xiaokui Mo, Melissa Vargo, David Jarjoura, John C. Byrd, Natarajan Muthusamy
ABSTRACT
The compromised antioxidant defense system in chronic lymphocytic leukemia (CLL) suggested a potential use for reactive oxygen species (ROS) generating arsenic trioxide (ATO) and ascorbic acid. While both ATO and ascorbic acid mediate cytotoxicity in CLL B cells as single agents, the efficacy of ATO is enhanced by ascorbic acid. This effect is dependent on increased ROS accumulation, as pretreatment of B-CLL cells with a glutathione reducing buthionine sulfoximine or catalase inhibiting aminotriazole,...
